Abstract
Background In the current era, there is always search for better cardiovascular biomarkers to early diagnose the disease. Objectives We aimed to investigate the association between a novel biomarker, cardiothropin-1 (CT-1), and standard markers of myocardial ischemia in patients with acute coronary syndrome (ACS) in Turkey. Patients and Methods In this prospective cohort study, patients who were admitted to our institution between July 2012 and July 2013 with the diagnosis of ACS were included. The standard markers of myocardial [...]
Highlights
Cardiovascular diseases are the major causes of mortality and morbidity, especially among the aging population.[1]
It is expected that CAD will take the number 1 place in the list of 2020 causes of death prepared by the World Health Organization[3] Similar studies examining coronary artery disease (CAD) associated mortality in European countries report that the aforementioned
The process starts with fatty streaks in the early stages of life[6], and ischemia usually results from acute rupture of vulnerable plaques[8] or as a result of long-lasting decreased coronary blood flow due to increasing coronary obstruction.[6]
Summary
Cardiovascular diseases are the major causes of mortality and morbidity, especially among the aging population.[1]. Objectives: We aimed to investigate the association between a novel biomarker, cardiothropin-1 (CT-1), and standard markers of myocardial ischemia in patients with acute coronary syndrome (ACS) in Turkey. The standard markers of myocardial necrosis and CT-1 were evaluated at the time of admission and after 6 hours. Changes in laboratory parameters were statistically tested and correlated with routinely used markers of myocardial ischemia. Conclusion: CT-1 is one of the novel biomarkers for cardiac injury. It is correlated with standard markers of myocardial ischemia and the results suggest that CT-1 can be used as a new biomarker.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
